Catalyst Biosciences Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Catalyst Biosciences is a biotechnology company focused on research and clinical development for rare disorders affecting the complement and coagulation systems. Its work is supported by a protease engineering platform that underpins two late-stage clinical programs in hemophilia and enables approaches such as subcutaneous administration of coagulation factors and complement inhibitors. The company is pursuing a discovery-stage Factor IX gene therapy construct for Hemophilia B and has a partnered preclinical program with Biogen addressing dry age-related macular degeneration.
Based in South San Francisco, California, Catalyst operates in the biotechnology research sector as a small to mid-sized company. In 2023, Catalyst announced asset transfers to GC Biopharma related to its rare-disease hematology programs, reflecting portfolio changes.

Sign up for free to view info

Company overview Employee directory